BHE Stock Analysis: Benchmark Electronics | NYSE
Electronic Components | NYSE, USA | Market Cap: 3.160m USD | 12M Return: 115.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 50.9M
EPS Trend: 95.5%
Qual. Beats: 3
Rev. Trend: -84.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Benchmark Electronics (NYSE: BHE) is a global provider of integrated product design, engineering, technology, and manufacturing services for original equipment manufacturers (OEMs) across the Americas, Asia, and Europe. The companys offerings span new product design, prototyping, and engineering; printed circuit board assembly and testing; subsystem and system-level integration; precision metal machining and electromechanical assembly; and full lifecycle support including supply chain management, direct order fulfillment, and aftermarket repair, refurbishment, and remanufacturing services.
BHE serves OEMs in advanced computing and communications, aerospace and defense, industrial, medical, and semiconductor capital equipment, primarily selling through a direct sales force. The company was founded in 1979 and is headquartered in Tempe, Arizona.
The company operates in the Electronic Manufacturing Services (EMS) industry, where contractors handle design, assembly, testing, and after-market support on behalf of OEMs that choose to outsource these functions. EMS providers typically generate revenue on a contract basis tied to OEM production volumes, with margins influenced by product mix, complexity, and exposure to higher-value verticals such as aerospace, defense, and medical devices. BHE has been publicly traded since 1990 and is classified within the Information Technology sector.
- Aerospace and defense segment expansion lifts margin mix
- Semiconductor capital equipment demand accelerates from global fab buildouts
- Medical device manufacturing revenue grows on healthcare spending
| Net Income: 34.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -2.45 > 1.0 |
| NWC/Revenue: 29.24% < 20% (prev 33.26%; Δ -4.02% < -1%) |
| CFO/TA 0.07 > 3% & CFO 139.5m > Net Income 34.2m |
| Net Debt (79.0m) to EBITDA (135.9m): 0.58 < 3 |
| Current Ratio: 2.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (36.3m) vs 12m ago -0.90% < -2% |
| Gross Margin: 10.10% > 18% (prev 10.09%; Δ 0.01% > 0.5%) |
| Asset Turnover: 127.8% > 50% (prev 122.3%; Δ 5.50% > 0%) |
| Interest Coverage Ratio: 4.87 > 6 (EBIT TTM 90.1m / Interest Expense TTM 18.5m) |
| A: 0.38 (Total Current Assets 1.46b - Total Current Liabilities 669.2m) / Total Assets 2.10b |
| B: 0.27 (Retained Earnings 570.5m / Total Assets 2.10b) |
| C: 0.04 (EBIT TTM 90.1m / Avg Total Assets 2.12b) |
| D: 1.10 (Book Value of Equity 1.10b / Total Liabilities 999.7m) |
| Altman-Z'' = 4.80 = AA |
| DSRI: 1.00 (Receivables 566.8m/546.1m, Revenue 2.70b/2.61b) |
| GMI: 1.00 (GM 10.09% / 10.10%) |
| AQI: 1.03 (AQ_t 0.14 / AQ_t-1 0.14) |
| SGI: 1.04 (Revenue 2.70b / 2.61b) |
| TATA: -0.05 (NI 34.2m - CFO 139.5m) / TA 2.10b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of July 10, 2026, the stock is trading at USD 85.26 with a total of 359,913 shares traded. Over the past week, the price has changed by -10.26%, over one month by -1.51%, over three months by +37.34% and over the past year by +115.21%.
Current recommended Stop Loss: 77.40 (which is 9.2% or 1.6 ATR below the current price).
Benchmark Electronics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy BHE.
- StrongBuy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 78 | -8.5% |
P/E Trailing = 93.6915
P/E Forward = 14.1443
P/S = 1.1425
P/B = 2.8181
P/EG = 1.328
Revenue TTM = 2.70b USD
EBIT TTM = 90.1m USD
EBITDA TTM = 135.9m USD
Long Term Debt = 201.0m USD (from longTermDebt, last quarter)
Short Term Debt = 3.75m USD (from shortTermDebt, last quarter)
Debt = 403.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 99.5m
Net Debt = 79.0m USD (calculated: Debt 403.9m - CCE 324.9m)
Enterprise Value = 3.24b USD (3.16b + Debt 403.9m - CCE 324.9m)
Interest Coverage Ratio = 4.87 (Ebit TTM 90.1m / Interest Expense TTM 18.5m)
EV/FCF = 37.30x (Enterprise Value 3.24b / FCF TTM 86.8m)
FCF Yield = 2.68% (FCF TTM 86.8m / Enterprise Value 3.24b)
FCF Margin = 3.21% (FCF TTM 86.8m / Revenue TTM 2.70b)
Net Margin = 1.27% (Net Income TTM 34.2m / Revenue TTM 2.70b)
Gross Margin = 10.10% ((Revenue TTM 2.70b - Cost of Revenue TTM 2.43b) / Revenue TTM)
Gross Margin QoQ = 10.24% (prev 10.40%)
Tobins Q-Ratio = 1.55 (Enterprise Value 3.24b / Total Assets 2.10b)
Interest Expense / Debt = 4.58% (Interest Expense 18.5m / Debt 403.9m)
Taxrate = 29.31% (5.40m / 18.4m)
NOPAT = 63.7m (EBIT 90.1m * (1 - 29.31%))
Current Ratio = 2.18 (Total Current Assets 1.46b / Total Current Liabilities 669.2m)
Debt / Equity = 0.37 (Debt 403.9m / totalStockholderEquity, last quarter 1.10b)
Debt / EBITDA = 0.58 (Net Debt 79.0m / EBITDA 135.9m)
Debt / FCF = 0.91 (Net Debt 79.0m / FCF TTM 86.8m)
Total Stockholder Equity = 1.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.62% (Net Income 34.2m / Total Assets 2.10b)
RoE = 3.10% (Net Income TTM 34.2m / Total Stockholder Equity 1.10b)
RoCE = 6.91% (EBIT 90.1m / Capital Employed (Equity 1.10b + L.T.Debt 201.0m))
RoIC = 4.92% (NOPAT 63.7m / Invested Capital 1.30b)
WACC = 10.36% (E(3.16b)/V(3.56b) * Re(11.27%) + D(403.9m)/V(3.56b) * Rd(4.58%) * (1-Tc(0.29)))
Discount Rate = 11.27% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -6.67 | Cagr: 0.39%
[DCF] Terminal Value 65.98% ; FCFF base≈108.4m ; Y1≈95.1m ; Y5≈76.8m
[DCF] Fair Price = 23.65 (EV 927.4m - Net Debt 79.0m = Equity 848.4m / Shares 35.9m; r=10.36% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 95.47 | EPS CAGR: 6.28% | SUE: 1.36 | # QB: 3
Revenue Correlation: -84.61 | Revenue CAGR: -3.99% | SUE: 0.05 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.69 | Chg30d=+15.74% | Revisions=+50% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.72 | Chg30d=+8.05% | Revisions=+50% | Analysts=3
EPS current Year (2026-12-31): EPS=2.75 | Chg30d=+7.98% | Revisions=+50% | GrowthEPS=+14.6% | GrowthRev=+9.3%
EPS next Year (2027-12-31): EPS=3.10 | Chg30d=+8.51% | Revisions=+50% | GrowthEPS=+12.8% | GrowthRev=+6.5%
[Analyst] Revisions Ratio: +80% (up=12, down=0)